{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:18:48Z","timestamp":1782962328291,"version":"3.54.5"},"reference-count":38,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>\n                    The global increase in carbapenem resistance poses a significant public health threat due to the potential emergence of multidrug-resistant pathogens and limited treatment options. To learn more about this issue and offer potential solutions, we conducted a study of carbapenem-resistant\n                    <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                    (CRPA) infections in a secondary care hospital setting. The study utilized the carbapenem inactivation method (CIM), a leading phenotypic analysis, to determine carbapenemase activity in 63 CRPA isolates. Additionally, polymerase chain reaction (PCR) analysis was conducted to test for the presence of carbapenemase genes associated with the production or expression of various carbapenemase enzymes, including\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    ,\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>NDM<\/jats:sub>\n                    ,\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>VIM<\/jats:sub>\n                    ,\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>OXA-48<\/jats:sub>\n                    ,\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>IMP<\/jats:sub>\n                    , and\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>GES<\/jats:sub>\n                    . Arbitrary primed PCR (AP-PCR) was performed to assess the clonal relationship between different isolates. The isolates were also classified as either health care-associated infections or community-acquired infections, and their clonal relationship and gene positivity were evaluated. A total of 63 CRPA samples underwent evaluation, with 14 isolates determined to be carbapenemase producers via CIM tests. PCR assays revealed that 14 isolates carried carbapenemase genes, with 9 carrying\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>NDM<\/jats:sub>\n                    , 2 carrying\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>GES<\/jats:sub>\n                    , 2 carrying\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>VIM<\/jats:sub>\n                    , and 1 carrying\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>IMP<\/jats:sub>\n                    . CRPA exhibited a 22% prevalence of carbapenemase genes, of which 64% were attributed to the NDM gene responsible for multidrug resistance. AP-PCR revealed high clonal diversity among the isolates. Molecular epidemiological evaluation also showed no dominant outbreak strain among PA isolates. This study presents significant data on the prevalence and distribution of carbapenemase-producing CRPA strains isolated from secondary health care facilities. Typically, the literature focuses on resistance rates in tertiary care public hospitals. These findings may aid in understanding resistance and its mechanisms, as well as in developing effective treatment strategies and infection control measures.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2024.0067","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T12:38:06Z","timestamp":1731501486000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Investigation of Carbapenemase-Producing\n                    <i>Pseudomonas aeruginosa<\/i>\n                    at Secondary Care Hospital in Bolu, Turkey"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-2940","authenticated-orcid":false,"given":"Zuhal","family":"Kalayc\u0131 \u00c7ekin","sequence":"first","affiliation":[{"name":"Clinical Microbiology Laboratory, Bolu Izzet Baysal State Hospital, Bolu, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Seren","family":"Tanr\u0131verdi","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Inonu University Faculty of Medicine, Molecular Microbiology Laboratory, Inonu University Turgut Ozal Medical Centre, Malatya, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar\u0131\u015f","family":"Otlu","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Inonu University Faculty of Medicine, Molecular Microbiology Laboratory, Inonu University Turgut Ozal Medical Centre, Malatya, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgar.2018.06.001","article-title":"Systematic review of the use of time series data in the study of antimicrobial consumption and Pseudomonas aeruginosa resistance","volume":"15","author":"Athanasiou CI","year":"2018","unstructured":"Athanasiou CI, , Kopsini A. Systematic review of the use of time series data in the study of antimicrobial consumption and Pseudomonas aeruginosa resistance. J Glob Antimicrob Resist, 2018; 15:69\u201373; doi: 10.1016\/j.jgar.2018.06.001","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ajic.2014.05.029","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007\u20132012. Device-associated module","volume":"42","author":"Rosenthal VD","year":"2014","unstructured":"Rosenthal VD, , Maki DG, , Mehta Y, et al. International Nosocomial Infection Control Consortium. International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007\u20132012. Device-associated module. Am J Infect Control, 2014; 42(9):942\u2013956; doi: 10.1016\/j.ajic.2014.05.029","journal-title":"Am J Infect Control"},{"issue":"1","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0974-777X.176142","article-title":"Incidence of multidrug-resistant Pseudomonas spp. in ICU patients with special reference to ESBL, AMPC, MBL and biofilm production","volume":"8","author":"Gupta R","year":"2016","unstructured":"Gupta R, , Malik A, , Rizvi M, et al. Incidence of multidrug-resistant Pseudomonas spp. in ICU patients with special reference to ESBL, AMPC, MBL and biofilm production. J Glob Infect Dis, 2016; 8(1):25\u201331; doi: 10.4103\/0974-777X.176142","journal-title":"J Glob Infect Dis"},{"issue":"12","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1099\/jmm.0.073262-0","article-title":"Pseudomonas aeruginosa bacteraemia: Independent risk factors for mortality and impact of resistance on outcome","volume":"63","author":"Dantas RC","year":"2014","unstructured":"Dantas RC, , Ferreira ML, , Gontijo-Filho PP, et al. Pseudomonas aeruginosa bacteraemia: Independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol, 2014; 63(Pt 12):1679\u20131687; doi: 10.1099\/jmm.0.073262-0","journal-title":"J Med Microbiol"},{"issue":"9","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","article-title":"The \u03b2-lactamase threat in enterobacteriaceae, Pseudomonas and Acinetobacter","volume":"14","author":"Livermore DM","year":"2006","unstructured":"Livermore DM, , Woodford N. The \u03b2-lactamase threat in enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol, 2006; 14(9):413\u2013420; doi: 10.1016\/j.tim.2006.07.008","journal-title":"Trends Microbiol"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"43034","DOI":"10.3389\/fmicb.2013.00048","article-title":"Stormy waters ahead: Global emergence of carbapenemases","volume":"4","author":"Patel G","year":"2013","unstructured":"Patel G, , Bonomo R. Stormy waters ahead: Global emergence of carbapenemases. Front Microbiol, 2013; 4:43034; doi: 10.3389\/fmicb.2013.00048","journal-title":"Front Microbiol"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0427"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0092"},{"issue":"3","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jac\/dks426","article-title":"Strategies for identification of carbapenemase-producing enterobacteriaceae","volume":"68","author":"Nordmann P","year":"2013","unstructured":"Nordmann P, , Poirel L. Strategies for identification of carbapenemase-producing enterobacteriaceae. J Antimicrob Chemother, 2013; 68(3):487\u2013489.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2008.03.002"},{"key":"e_1_3_6_13_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing Breakpoint tables forinterpretation of MICs and zone diameters. 2023 Version 13.0; http:\/\/www.eucast.org"},{"issue":"8","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JCM.00193-17","article-title":"Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among enterobacteriaceae","volume":"55","author":"Pierce VM","year":"2017","unstructured":"Pierce VM, , Simner PJ, , Lonsway DR, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among enterobacteriaceae. J Clin Microbiol, 2017; 55(8):2321\u20132333; doi: 10.1128\/JCM.00538-17","journal-title":"J Clin Microbiol"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.12.002"},{"issue":"8","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1128\/AAC.00171-08","article-title":"Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic","volume":"52","author":"Kiratisin P","year":"2008","unstructured":"Kiratisin P, , Apisarnthanarak A, , Laesripa C, et al. Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother, 2008; 52(8):2818\u20132824; doi: 10.1128\/aac.00171-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ajic.2022.10.012","article-title":"A long-lasting Sphingomonas paucimobilis outbreak: A potential for pathogens to persist on environmental devices despite disinfection measures","volume":"51","author":"Menek\u015fe \u015e","year":"2023","unstructured":"Menek\u015fe \u015e, , Tanr\u0131verdi ES, , Alt\u0131nay E, et al. A long-lasting Sphingomonas paucimobilis outbreak: A potential for pathogens to persist on environmental devices despite disinfection measures. Am J Infect Control, 2023; 51(7):765\u2013771; doi: 10.1016\/j.ajic.2022.10.012","journal-title":"Am J Infect Control"},{"key":"e_1_3_6_18_2","unstructured":"EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance Version 2. 2017. http:\/\/www.eucast.org\/"},{"issue":"8","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1128\/AAC.33.8.1202","article-title":"Decreased outer membrane permeability in imipenem resistant mutants of Pseudomonas aeruginosa","volume":"33","author":"Trias J","year":"1989","unstructured":"Trias J, , Dufresne J, , Levesque RC, et al. Decreased outer membrane permeability in imipenem resistant mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1989; 33(8):1202\u20131206; doi: 10.1128\/aac.33.8.1202","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12941-014-0043-3","article-title":"Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance","volume":"13","author":"Rizek C","year":"2014","unstructured":"Rizek C, , Fu L, , Dos Santos LC, et al. Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance. Ann Clin Microbiol Antimicrob, 2014; 13:43\u201345; doi: 10.1186\/s12941-014-0043-3","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"7","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseuomonas aeruginosa collected during 2009\u201311 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira M","year":"2014","unstructured":"Castanheira M, , Deshpande LM, , Costello A, et al. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseuomonas aeruginosa collected during 2009\u201311 in 14 European and Mediterranean countries. J Antimicrob Chemother, 2014; 69(7):1804\u20131814; doi: 10.1093\/jac\/dku048","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","article-title":"Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology","volume":"45","author":"Potron A","year":"2015","unstructured":"Potron A, , Poirel L, , Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents, 2015; 45(6):568\u2013585; doi: 10.1016\/j.ijantimicag.2015.03.001","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/antibiotics10050548","article-title":"Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa","volume":"10","author":"Wang MG","year":"2021","unstructured":"Wang MG, , Liu ZY, , Liao XP, et al. Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel), 2021; 10(5):548; doi: 10.3390\/antibiotics10050548","journal-title":"Antibiotics (Basel)"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-15"},{"issue":"6","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JCM.02874-20","article-title":"Antimicrobial susceptibility profiles to predict the presence of carbapenemase genes among carbapenem-resistant Pseudomonas aeruginosa isolates","volume":"59","author":"Vallabhaneni S","year":"2021","unstructured":"Vallabhaneni S, , Huang JY, , Grass JE, et al. EIP Work Group. Antimicrobial susceptibility profiles to predict the presence of carbapenemase genes among carbapenem-resistant Pseudomonas aeruginosa isolates. J Clin Microbiol, 2021; 59(6):10\u20131128; doi: 10.1128\/jcm.02874-20","journal-title":"J Clin Microbiol"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0012"},{"issue":"1","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"115174","DOI":"10.1016\/j.diagmicrobio.2020.115174","article-title":"Carbapenemase-producing Pseudomonas aeruginosa isolates from Turkey: First report of P. aeruginosa high-risk clones with VIM-5\u2013and IMP-7\u2013type carbapenemases in a tertiary hospital","volume":"99","author":"\u00c7ekin ZK","year":"2021","unstructured":"\u00c7ekin ZK, , Dabos L, , Malko\u00e7o\u011flu G, et al. Carbapenemase-producing Pseudomonas aeruginosa isolates from Turkey: First report of P. aeruginosa high-risk clones with VIM-5\u2013and IMP-7\u2013type carbapenemases in a tertiary hospital. Diagn Microbiol Infect Dis, 2021; 99(1):115174.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"e_1_3_6_28_2","article-title":"VIM, NDM, IMP, GES, SPM, GIM, SIM Metallobetalactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from a Turkish university hospital","volume":"10","author":"Cayci YT","year":"2022","unstructured":"Cayci YT, , Biyik I, , Birinci A. VIM, NDM, IMP, GES, SPM, GIM, SIM Metallobetalactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from a Turkish university hospital. J Arch Mil Med, 2022; 10(1); doi: 10.5812\/jamm-118712","journal-title":"J Arch Mil Med"},{"key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2147\/IDR.S299742","article-title":"Screening of antimicrobial resistance genes and epidemiological features in hospital and community-associated carbapenem-resistant Pseudomonas aeruginosa infections","volume":"14","author":"\u00c7opur \u00c7\u0131\u00e7ek A","year":"2021","unstructured":"\u00c7opur \u00c7\u0131\u00e7ek A, , Ert\u00fcrk A, , Ejder N, et al. Screening of antimicrobial resistance genes and epidemiological features in hospital and community-associated carbapenem-resistant Pseudomonas aeruginosa infections. Infect Drug Resist, 2021; 14:1517\u20131526; doi: 10.2147\/IDR.S299742","journal-title":"Infect Drug Resist"},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"614058","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile carbapenemase genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon EJ","year":"2021","unstructured":"Yoon EJ, , Jeong SH. Mobile carbapenemase genes in Pseudomonas aeruginosa. Front Microbiol, 2021; 12:614058; doi: 10.3389\/fmicb.2021.614058","journal-title":"Front Microbiol"},{"key":"e_1_3_6_31_2","unstructured":"Center for Disease Control and Prevention. 2019 AR threats report. Available from: https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html [Last accessed: May8 2019]."},{"key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jgar.2019.01.032","article-title":"Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis","volume":"18","author":"Acar A","year":"2019","unstructured":"Acar A, , Karaahmeto\u011flu G, , Akal\u0131n H, et al. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: A meta-analysis. J Glob Antimicrob Resist, 2019; 18:64\u201370; doi: 10.1016\/j.jgar.2019.01.032","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011-2012)","volume":"57","author":"Farrell DJ","year":"2013","unstructured":"Farrell DJ, , Flamm RK, , Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011-2012). Antimicrob Agents Chemother, 2013; 57(12):6305\u20136310; doi: 10.1128\/AAC.01802-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozanetazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: A multicenter study","volume":"5","author":"Gallagher JC","year":"2018","unstructured":"Gallagher JC, , Satlin MJ, , Elabor A, et al. Ceftolozanetazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: A multicenter study. Open Forum Infect Dis, 2018; 5(11):ofy280; doi: 10.1093\/ofid\/ofy280","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader HS","year":"2014","unstructured":"Sader HS, , Farrell DJ, , Castanheira M, et al. Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312). J Antimicrob Chemother, 2014; 69(10):2713\u20132722; doi: 10.1093\/jac\/dku184","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"e00465","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from the PACTS antimicrobial surveillance program, 2012 to 2015","volume":"61","author":"Shortridge D","year":"2017","unstructured":"Shortridge D, , Castanheira M, , Pfaller MA, et al. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob Agents Chemother, 2017; 61(7):e00465; doi: 10.1128\/AAC.00465-17","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1478"},{"issue":"7","key":"e_1_3_6_38_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3201\/eid2507.181200","article-title":"Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015","volume":"25","author":"Walters MS","year":"2019","unstructured":"Walters MS, , Grass JE, , Bulens SN, et al. Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg Infect Dis, 2019; 25(7):1281\u20131288; doi: 10.3201\/eid2507.181200","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"e_1_3_6_39_2","first-page":"355","article-title":"Applications of PCR techniques for molecular epidemiology of infectious diseases","volume":"22","author":"Fern\u00e1ndez-Cuenca F","year":"2004","unstructured":"Fern\u00e1ndez-Cuenca F. Applications of PCR techniques for molecular epidemiology of infectious diseases. Enferm Infecc Microbiol Clin, 2004; 22(6):355\u2013360; doi: 10.1016\/s0213-005x(04)73108-0","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2024.0067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:41:39Z","timestamp":1777668099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2024.0067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1089\/mdr.2024.0067"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2024.0067","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}